In Re: Zetia (Ezetimibe) Antitrust Litigation

Track this case

Case overview

Case Number:

2:18-md-02836

Court:

Virginia Eastern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Rebecca Beach Smith

Firms

Companies

Sectors & Industries:

August 24, 2020
Zetia Buyers Granted Cert. Despite Small Class Size

A Virginia federal judge granted class certification Friday to Zetia direct buyers accusing Merck and Glenmark Pharmaceuticals of conspiring to keep a generic version of the cholesterol drug off the market, rejecting attacks on the small size of the class and the companies representing them.
August 17, 2020
Zetia Buyers Win Recommendation For Class Cert.

A federal magistrate judge has recommended that a group of Zetia buyers be granted class certification in a dispute accusing Merck and Glenmark Pharmaceuticals of conspiring to keep a generic version of the cholesterol drug off the market.
July 07, 2020
Merck, Glenmark Implore Court To Reject Zetia Class Cert.

Merck and Glenmark Pharmaceuticals are trying to convince a Virginia federal court to smack down a magistrate's recommendation to certify a class of direct purchasers who have accused the duo of conspiring to keep a generic version of the cholesterol drug Zetia off the market.
May 06, 2020
Zetia Buyers Blast Merck's 'Unhinged' Bid To Eject Class Rep

A proposed class of drug buyers is coming out swinging after the second of two "desperate efforts" to unseat its lead plaintiff in a suit accusing Merck and Glenmark Pharmaceuticals of teaming up to keep a generic version of the cholesterol drug Zetia off the market.
March 09, 2020
Judge OKs Par's Settlement In Zetia Pay-For-Delay Case

A Virginia federal judge has given the final greenlight to a settlement that knocks Par Pharmaceutical out of a massive suit accusing Merck and Glenmark of plotting to hold off generic versions of Zetia and inflating the cholesterol drug's costs.
December 23, 2019
Zetia Buyers' Lose Antitrust Claims Against Merck, Glenmark

Drug wholesalers and retailers alleging Merck, Glenmark and Par Pharmaceuticals were part of a conspiracy to keep generic versions of cholesterol drug Zetia off the market can't sue Merck and Glenmark for overcharges they purportedly paid for Glenmark's generic, a Virginia federal judge ruled.
November 19, 2019
Direct Buyers Seek Cert. In Zetia Generic Delay Suit

Direct drug buyers accusing Merck and Glenmark of conspiring to keep a generic version of the cholesterol drug Zetia off the market have urged a Virginia federal judge to certify their class, saying the alleged conspiracy forced the class members to pay higher prices.
October 30, 2019
Zetia Generic Delay Was A Conspiracy, Court Told

A Virginia federal judge was wrong to recommend that drugmakers Merck and Glenmark be cleared of allegations that they were part of a three-way conspiracy to keep a generic version of the cholesterol drug Zetia off the market, direct drug buyers said Tuesday.
October 29, 2019
Retailers Fight To Keep 3-Way Zetia Conspiracy Claim In MDL

Kroger, Walgreens and a host of other retailers urged a Virginia federal judge Tuesday not to take up a magistrate's recommendation to clear Merck and Glenmark of allegations that they were part of a three-way conspiracy to keep a generic version of the cholesterol drug Zetia off the market.
October 16, 2019
Toss 3-Way Zetia Conspiracy Claim, Judge Says

A group of direct purchaser plaintiffs may find it harder to prove a pay-for-delay scheme over a generic version of Merck's Zetia after a Virginia federal judge recommended Tuesday that the drugmaker and generics company Glenmark be cleared of allegations of a three-way conspiracy with Glenmark's distributor, Par Pharmaceuticals.